Literature DB >> 11710918

Skin-homing interleukin-4 and -13-producing cells contribute to bullous pemphigoid: remission of disease is associated with increased frequency of interleukin-10-producing cells.

Y Teraki1, T Hotta, T Shiohara.   

Abstract

Although evidence is accumulating that type 2 cytokines play a part in the pathogenesis of bullous pemphigoid, little information is available concerning characterization of the cellular source of these cytokines involved in the pathogenesis of bullous pemphigoid. By using multiparameter flow cytometry, we investigated T cells capable of producing interleukin-2, -4, -10, and -13, interferon-gamma, and tumor necrosis factor-alpha and their correlated expression of skin-homing receptor (cutaneous lymphocyte-associated antigen) in peripheral blood and skin blister of patients with bullous pemphigoid. In peripheral blood of bullous pemphigoid patients, significantly increased frequencies of interleukin-4- and interleukin-13-producing cells were found as compared with those of healthy controls, and the majority of these type 2 cells was found in the cutaneous lymphocyte-associated antigen-positive population. The frequency of interferon-gamma-producing cells was also increased as compared with healthy subjects; however, the majority of this subset was found in the cutaneous lymphocyte-associated antigen-negative population. In the skin blister, the frequencies of interleukin-13- and interleukin-4-producing cells were much higher than those in the peripheral blood of bullous pemphigoid, whereas that of interferon-gamma producing cells was significantly lower. Furthermore, in bullous pemphigoid patients after therapy with systemic corticosteroids, the frequency of cutaneous lymphocyte-associated antigen-positive, but not cutaneous lymphocyte-associated antigen-negative, interleukin-13-producing cells was significantly decreased accompanied by an increased frequency of interleukin-10-producing cells, which was associated with clinical improvement. Thus, our results suggest that bullous pemphigoid is a unique organ-specific autoimmune disease characterized by an expansion of skin-homing interleukin-13-producing cells. In addition, corticosteroids may control such type 2 biased inflammatory responses in bullous pemphigoid by promoting the expansion of interleukin-10-producing cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11710918     DOI: 10.1046/j.0022-202x.2001.01505.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  13 in total

Review 1.  Pemphigus and Pemphigoid: From Disease Mechanisms to Druggable Pathways.

Authors:  Christoph T Ellebrecht; Damian Maseda; Aimee S Payne
Journal:  J Invest Dermatol       Date:  2021-10-29       Impact factor: 7.590

2.  Interleukin-16 expression and release in bullous pemphigoid.

Authors:  A Frezzolini; G Cianchini; M Ruffelli; S Cadoni; P Puddu; O De Pità
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

Review 3.  The Intersection of IgE Autoantibodies and Eosinophilia in the Pathogenesis of Bullous Pemphigoid.

Authors:  Kelly N Messingham; Tyler P Crowe; Janet A Fairley
Journal:  Front Immunol       Date:  2019-10-04       Impact factor: 7.561

4.  Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid.

Authors:  S Morteza Seyed Jafari; Laurence Feldmeyer; Simon Bossart; Dagmar Simon; Christoph Schlapbach; Luca Borradori
Journal:  Front Immunol       Date:  2021-01-29       Impact factor: 7.561

5.  IL-13 Genetic Susceptibility to Bullous Pemphigoid: A Potential Target for Treatment and a Prognostic Marker.

Authors:  Yiman Wang; Xuming Mao; Yangchun Liu; Yuyan Yang; Hongzhong Jin; Li Li
Journal:  Front Immunol       Date:  2022-01-24       Impact factor: 7.561

6.  Interleukin-4 promotes human CD8 T cell expression of CCR7.

Authors:  Suranjith L Seneviratne; Antony P Black; Louise Jones; Kati di Gleria; Abigail S Bailey; Graham S Ogg
Journal:  Immunology       Date:  2006-10-31       Impact factor: 7.397

7.  IgE autoreactivity in bullous pemphigoid: eosinophils and mast cells as major targets of pathogenic immune reactants.

Authors:  P C Freire; C H Muñoz; G Stingl
Journal:  Br J Dermatol       Date:  2017-11-28       Impact factor: 9.302

8.  Regulatory effects of Nr4a2 on Th2 cells from patients with pemphigus vulgaris.

Authors:  Jianbo Chen; Yao Zhang; Yunsheng Liang; Ming Zhao; Hai Long; Rong Xiao; Haijing Wu; Jieyue Liao; Shuaihantian Luo; Guiying Zhang; Qianjin Lu
Journal:  Oncotarget       Date:  2018-02-01

9.  Targeting interleukin 4 receptor α: A new approach to the treatment of cutaneous autoimmune bullous diseases?

Authors:  Roberto Russo; Emanuele Cozzani; Giulia Gasparini; Aurora Parodi
Journal:  Dermatol Ther       Date:  2020-01-02       Impact factor: 2.851

Review 10.  Emerging Biomarkers and Therapeutic Strategies for Refractory Bullous Pemphigoid.

Authors:  Tong Zhou; Bin Peng; Songmei Geng
Journal:  Front Immunol       Date:  2021-08-24       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.